CLINICAL TRIAL

Treatment for Ito Syndrome

Recruiting · 18 - 65 · All Sexes · Dallas, TX

Intense Pulsed Light Therapy Combined With a Fractionated 1927nm Laser for Diffuse Pigmentation and Actinic Changes.

See full description

About the trial for Ito Syndrome

Eligible Conditions
Pigmentation Disorders · Skin Pigment

Treatment Groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex between 18 and 65 years old. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Healthy male and female adults between 20-60 years of age.
You have a skin type of I-IV. show original
Individuals deemed by the Investigator to have a significant amount of pigmentation/melasma and that desire correction of this condition.
Individuals willing to withhold aesthetic therapies, or other therapies judged to potentially impact results to the treatment areas for the duration of the study.
Barrier methods with spermicide: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
Intrauterine device (IUD) or intrauterine system (IUS)
Surgical sterilization (e.g. vasectomy confirmed to be effective by sperm count check, tubal occlusion, hysterectomy, bilateral salpingectomy/oophorectomy)
Abstinence from heterosexual intercourse, when this is in line with the preferred and usual lifestyle of the subject show original
You have used hormonal contraception for at least 6 months. show original
You are a woman of childbearing potential who agrees to take a urine pregnancy test at the Screening visit or when deemed by Investigator show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Through study completion, an average of 10 months
Screening: ~3 weeks
Treatment: Varies
Reporting: Through study completion, an average of 10 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Through study completion, an average of 10 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome and 4 secondary outcomes in patients with Ito Syndrome. Measurement will happen over the course of Baseline and 3 Months.

Change from Baseline of red areas at 3 Months
BASELINE AND 3 MONTHS
Numeric analysis of red areas will be analyzed using Vectra H2 3D analysis. Standard, close up and cross-polarized photography will be utilized for evaluation of pigmentation.
BASELINE AND 3 MONTHS
Change from Baseline of Vasculature Density
THROUGH STUDY COMPLETION, AN AVERAGE OF 10 MONTHS
Optical Coherence Topographic (OCT)/histological images will be obtained to evaluate vasculature density.
THROUGH STUDY COMPLETION, AN AVERAGE OF 10 MONTHS
Adverse Events
THROUGH STUDY COMPLETION, AN AVERAGE OF 10 MONTHS
The study team will monitor incidence, severity, and relatedness of adverse events throughout the study.
THROUGH STUDY COMPLETION, AN AVERAGE OF 10 MONTHS
Change from Baseline of Skin Tissue Density
THROUGH STUDY COMPLETION, AN AVERAGE OF 10 MONTHS
Optical Coherence Topographic (OCT)/histological images will be obtained to evaluate skin tissue density.
THROUGH STUDY COMPLETION, AN AVERAGE OF 10 MONTHS
Change from Baseline of Skin Thickness
THROUGH STUDY COMPLETION, AN AVERAGE OF 10 MONTHS
Optical Coherence Topographic (OCT)/histological images will be obtained to evaluate skin thickness.
THROUGH STUDY COMPLETION, AN AVERAGE OF 10 MONTHS

Who is running the study

Principal Investigator
A. C.
Prof. Abby Culver, Assistant Professor
University of Texas Southwestern Medical Center

Patient Q & A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.

See if you qualify for this trial
Get access to this novel treatment for Ito Syndrome by sharing your contact details with the study coordinator.